Taken together, we observed in 3 independent models and cancer lineages that VRK1 depletion leads to tumor repression in vivo, suggesting that VRK1 is a potential therapeutic target in VRK2 promoter–methylated adult and pediatric gliomas and neuroblastomas. Here, VRK2 is linked to neoplasm.